Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   36116   clinical trials with a EudraCT protocol, of which   5936   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2010-019685-87
    Sponsor's Protocol Code Number:RO-2455-404-RD
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2011-11-03
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2010-019685-87
    A.3Full title of the trial
    Effect of roflumilast on exacerbation rate in patients with COPD treated with fixed combinations of LABA and ICS. A 52-week, randomised double-blind trial with roflumilast 500 ?g versus placebo
    Efecto de roflumilast sobre la tasa de exacerbaciones en pacientes con EPOC tratados con combinaciones fijas de ABAP y GCI. Ensayo doble ciego y aleatorizado de 52 semanas con roflumilast 500 microgramos frente a placebo.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    The trial investigates the effect of 500 ?g roflumilast tablets once daily
    versus placebo on exacerbation rate and pulmonary function in patients
    with Chronic Obstructive Pulmonary Disease (COPD) who are treated
    with a fixed combination of long-acting ?2-agonists (LABA) and inhaled
    glucocorticosteroids (ICS). Additionally it provides data on safety and
    tolerability in COPD patients treated with a fixed combination of LABA
    and ICS.
    El ensayo investiga el efecto de los comprimidos de roflumilast 500 ?g una vez al día frente a placebo sobre la tasa de exacerbación y la función pulmonar en pacientes con enfermedad pulmonar obstructiva crónica (EPOC) que están tratados con una combinación fija de agonistas ?2 de acción prolongada (ABAP) y glucocorticoides inhalados (GCI). Además, proporciona datos de seguridad y tolerabilidad en pacientes con EPOC tratados con una combinación fija de ABAP y de GCI.
    A.3.2Name or abbreviated title of the trial where available
    REACT
    A.4.1Sponsor's protocol code numberRO-2455-404-RD
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorNycomed GmbH
    B.1.3.4CountryGermany
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportNycomed GmbH
    B.4.2CountryGermany
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationNycomed GmbH
    B.5.2Functional name of contact pointDr. Esther Kruttschnitt (PM),
    B.5.3 Address:
    B.5.3.1Street AddressByk-Gulden-Str. 2
    B.5.3.2Town/ cityKonstanz
    B.5.3.3Post code78467
    B.5.3.4CountryGermany
    B.5.4Telephone number49 (0)7531 84-4173
    B.5.5Fax number+49 (0)7531 84-94173
    B.5.6E-mailesther.kruttschnitt@nycomed.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Daxas 500 microgramos comprimidos recubiertos con película
    D.2.1.1.2Name of the Marketing Authorisation holderNycomed GmbH
    D.2.1.2Country which granted the Marketing AuthorisationSpain
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.2Product code BY217
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNROFLUMILAST
    D.3.9.1CAS number 162401323
    D.3.9.2Current sponsor codeBY217
    D.3.9.3Other descriptive nameN/A
    D.3.10 Strength
    D.3.10.1Concentration unit µg microgram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number500
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboFilm-coated tablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Severe chronic obstructive pulmonary disease (COPD)
    Enfermedad pulmonar obstructiva crónica (EPOC) severa.
    E.1.1.1Medical condition in easily understood language
    In all patient information material COPD is used. There is no term in trivial language available.
    En todos los materiales de información a los pacientes se emplea EPOC. No existe en el lenguaje ningún término común .
    E.1.1.2Therapeutic area Diseases [C] - Respiratory Tract Diseases [C08]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 14.0
    E.1.2Level LLT
    E.1.2Classification code 10010952
    E.1.2Term COPD
    E.1.2System Organ Class 10038738 - Respiratory, thoracic and mediastinal disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To investigate the effect of roflumilast 500 ?g tablets once daily versus placebo on exacerbation rate and pulmonary function in COPD patients who are concomitantly treated with a fixed combination of long-acting ?2-agonists (LABA) and inhaled glucocorticosteroids (ICS).

    To obtain data on safety and tolerability of roflumilast in COPD patients concomitantly treated with a fixed combination of LABA and ICS.

    To further characterise the population pharmacokinetic profile of roflumilast and roflumilast N-oxide.

    To further characterise the pharmacokinetics/pharmacodynamics (PK/PD) relationship of roflumilast, roflumilast N-oxide and ?total phosphodiesterase 4 inhibitory? activity (tPDE4i) in terms of efficacy and relevant safety aspects.
    Investigar el efecto del roflumilast comprimidos de 500 microgramos una vez al día frente a placebo en la tasa de exacerbaciones y la función pulmonar en pacientes con EPOC que reciben tratamiento
    simultáneo con una combinación fija de agonistas Beta2 de acción prolongada (ABAP) y glucocorticoides inhalados (GCI).

    Obtener datos sobre la seguridad y tolerabilidad del roflumilast en
    los pacientes con EPOC que reciben tratamiento simultáneo con una combinación fija de ABAP y GCI.

    Definir mejor la farmacocinética poblacional de roflumilast y del N-óxido de roflumilast.

    Definir mejor la relación farmacocinética/farmacodinámica (FC/FD) del roflumilast, del N-óxido de roflumilast y la actividad inhibidora total sobre la fosfodiesterasa 4 (tPDE4i) en términos de eficacia y de aspectos de seguridad relevantes.
    E.2.2Secondary objectives of the trial
    Please refer to section E.2.1
    Ver sección E.2.1
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Giving written informed consent
    2. History of COPD (according to GOLD 2009) for at least 12 months prior to baseline Visit V0 associated with chronic productive cough for 3 months in each of the 2 years prior to baseline Visit V0 (with other causes of productive cough excluded)
    3. Age ? 40 years
    4. Forced expiratory volume after one second (FEV1)/forced vital capacity (FVC) ratio (post-bronchodilator) < 70%
    5. FEV1 (post-bronchodilator) ? 50% of predicted
    6. At least two documented moderate or severe COPD exacerbations
    7. Patients must be pre-treated with fixed combinations of LABA and ICS at a constant dose (maximum approved dosage strength of the combination) for at least 12 months prior to baseline Visit V0 separated by at least 10 days, within one year prior to baseline Visit V0
    8. Former smoker (defined as smoking cessation at least one year ago) or current smoker both with a smoking history of at least 20 pack years
    1. Consentimiento informado por escrito
    2. Antecedentes de EPOC (según la guía GOLD de 2009) durante al menos 12 meses antes de la visita basal V0 asociada a tos productiva crónica durante 3 meses en cada uno de los 2 años previos a la visita basal V0 (habiéndose excluido otras causas de tos productiva)
    3. Edad ? 40 años
    4. Razón volumen espiratorio forzado en el primer segundo (FEV1)/capacidad vital forzada (FVC) (después del broncodilatador) < 70%
    5. FEV1 (después del broncodilatador) ? 50% del valor previsto
    6. Al menos dos exacerbaciones moderadas o graves de la EPOC documentadas, separadas por al menos 10 días, en el año anterior a la visita basal V0
    7. Los pacientes deberán haber sido tratados con combinaciones fijas de ABAP y GCI en una dosis constante (dosis aprobada máxima de la combinación) durante al menos 12 meses antes de la visita basal V0
    8. Exfumador (definido como abandono del consumo de tabaco hace al menos un año) o fumador activo con antecedentes de tabaquismo de al menos 20 cajetillas-años
    E.4Principal exclusion criteria
    Criteria affecting the read-out parameters of the trial:
    1. Moderate or severe COPD exacerbation and/or COPD exacerbations treated with antibiotics ongoing at the baseline Visit V0
    2. Lower respiratory tract infection not resolved 4 weeks prior to the baseline Visit V0
    3. Diagnosis of asthma and/or other relevant lung disease (e.g. history of primary bronchiectases, cystic fibrosis, bronchiolitis, lung resection, lung cancer, interstitial lung disease [e.g. fibrosis, silicosis, sarcoidosis], or active tuberculosis)
    4. Current participation in a pulmonary rehabilitation program or completion of a pulmonary rehabilitation program within 3 months preceding the baseline Visit V0
    5. Known alpha-1-antitrypsin deficiency

    Criteria within ethical considerations in terms of general health:
    6. Clinically relevant abnormal laboratory values suggesting an undiagnosed disease requiring further clinical evaluation (as assessed by the Investigator)
    7. Severe psychiatric or neurological disorders
    8. History of depression associated with suicidal ideation or behaviour
    9. Congestive heart failure severity grade IV according to NYHA (New York Heart Association Functional Classification)
    10. Haemodynamically significant cardiac arrhythmias or heart valve deformations
    11. Computed tomography (CT) or chest x-ray findings indicating an acute pulmonary disease other than COPD (e.g. tuberculosis, severe bronchiectasis, tumours)
    12. Severe immunological diseases (e.g. known HIV infection, multiple sclerosis, lupus erythematosus, progressive multifocal leukoencephalopathy)
    13. Liver impairment Child-Pugh B or C and/or active viral hepatitis
    14. Severe acute infectious diseases (e.g. tuberculosis, or acute hepatitis)
    15. Any diagnosis of a malignant disease (except basal cell carcinoma) within 5 years before trial start
    16. Alcohol or drug abuse within the past year
    17. Suspected hypersensitivity to roflumilast or rescue medication or ingredients thereof, or any other contraindication for the use thereof
    18. Female patients of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire trial duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, unless they are surgically sterilized/hysterectomised or post-menopausal > 1 year or who are not using any other method of contraception considered sufficiently reliable by the Investigator in individual cases
    19. Pregnancy, breast feeding, planned oocyte donation or oocyte implantation
    20. Planned donation of germ cells, blood, organs or bone marrow during the course of the trial
    21. Participation in another trial (use of investigational product) within 30 days preceding the baseline Visit V0 or re-entry of patients previously enrolled in this trial
    22. Suspected inability or unwillingness to comply with trial procedures (e.g. language problems, psychological disorders, number and timing of visits at the site)
    23. Suffering from any concomitant disease that might interfere with trial procedures or evaluations
    24. Use of disallowed drugs (see below)
    25. Employee at the investigational site, relative or spouse of the Investigator
    Criterios que influyen en los parámetros de salida del ensayo:
    1. Exacerbación moderada o grave de la EPOC3 y/o exacerbaciones de la EPOC tratadas con antibióticos en curso en la visita basal V0
    2. Infección de las vías respiratorias inferiores no resuelta 4 semanas antes de la visita basal V0
    3. Diagnóstico de asma y/o cualquier otra enfermedad pulmonar importante (por ejemplo, antecedentes de bronquiectasias primarias, fibrosis quística, bronquiolitis, resección pulmonar, cáncer de pulmón, enfermedad pulmonar intersticial [por ejemplo, fibrosis, silicosis, sarcoidosis], o tuberculosis activa)
    4. Participación actual en un programa de rehabilitación pulmonar o finalización de un programa de rehabilitación pulmonar en los 3 meses previos a la visita basal V0
    5. Déficit conocido de alfa-1-antitripsina Criterios en los aspectos éticos relacionados con la salud general:
    6. Valores analíticos anómalos clínicamente relevantes que indiquen una enfermedad no diagnosticada que requiere una evaluación clínica adicional (según el criterio del investigador)
    7. Trastornos psiquiátricos o neurológicos graves
    8. Antecedentes de depresión asociada a ideas o conductas suicidas
    9. Intensidad de la insuficiencia cardíaca congestiva de grado IV según la NYHA (clasificación funcional de la New York Heart Association)
    10. Arritmias cardíacas o deformación de las válvulas cardíacas hemodinámicamente significativas
    11. Resultados de la radiografía de tórax o de la tomografía computarizada (TC) que indiquen una enfermedad pulmonar aguda aparte de la EPOC (por ejemplo, tuberculosis, bronquiectasia intensa grave, tumores)
    12. Enfermedades inmunológicas graves (por ejemplo, infección por el VIH, esclerosis múltiple, lupus eritematoso, leucoencefalopatía multifocal progresiva)
    13. Insuficiencia hepática Child-Pugh B o C y/o o hepatitis vírica activa
    14. Enfermedades infecciosas agudas graves (por ejemplo, tuberculosis o hepatitis aguda) 15. Cualquier diagnóstico de una neoplasia maligna (excepto carcinoma basocelular) en los 5 años previos al comienzo del ensayo
    16. Alcoholismo o toxicomanía en el año previo
    17. Sospecha de hipersensibilidad al roflumilast o a la medicación de rescate o a sus componentes, o cualquier otra contraindicación para su uso
    18. Mujeres con capacidad reproductiva, que no estén utilizando y no deseen seguir utilizando un método anticonceptivo médicamente fiable durante todo el ensayo, como anticonceptivos orales, inyectables o implantables, o dispositivos intrauterinos, a menos que hayan sido quirúrgicamente esterilizadas/histerectomizadas o lleven más de un año en fase posmenopáusica o que no utilicen ningún otro método anticonceptivo considerado suficientemente fiable por el investigador en casos concretos
    19. Embarazo, lactancia materna, previsión de donación o de implantación de ovocitos 20. Previsión de donación de células germinales, sangre, órganos o médula ósea durante el estudio
    21. Participación en otro ensayo (uso de un producto en investigación) en los 30 días previos a la visita basal V0 o reentrada de pacientes previamente incluidos en este ensayo
    22. Sospecha de incapacidad o de falta de disposición para seguir los procedimientos del ensayo (por ejemplo, problemas de lenguaje, trastornos psicológicos,
    número y fechas de las visitas al centro)
    23. Cualquier enfermedad concomitante que pudiera interferir en los procedimientos o las evaluaciones del ensayo
    24. Uso de medicamentos prohibidos (véase más adelante)
    25. Empleado en el centro de investigación, familiar o cónyuge del investigador
    E.5 End points
    E.5.1Primary end point(s)
    Rate of moderate or severe COPD exacerbations per patient per year. Moderate exacerbations are defined as requiring oral or parenteral glucocorticosteroids, severe as requiring hospitalisation and/or leading to death
    Tasa de exacerbaciones moderadas o graves de la EPOC por paciente y año. Las exacerbaciones moderadas se definen como aquellas que requieren glucocorticoides orales o parenterales; las exacerbaciones graves son aquellas que precisan hospitalización o que causan la muerte.
    E.5.1.1Timepoint(s) of evaluation of this end point
    The 1-year treatment period is considered appropriate to investigate the
    primary endpoint, reduction of exacerbation rate, taking into account the
    seasonal variation of COPD exacerbations during the year
    El periodo de tratamiento de un año se considera adecuado para investigar la variable principal, la reducción de la tasa de exacerbación, teniendo en cuenta la variación estacional de las exacerbaciones de la EPOC durante el año.
    E.5.2Secondary end point(s)
    Key secondary Endpoint - Change from randomisation (V2) over 52
    weeks of treatment in post-bronchodilator FEV1 [L]
    Other secondary endpoints:
    The COPD categories analysed include: mild; moderate; severe;
    moderate or severe; mild, moderate or severe; COPD exacerbations
    treated with systemic glucocorticosteroids and/or antibiotics; COPD
    exacerbations treated with antibiotics only; moderate or severe and/or
    treated with antibiotics, and CRF COPD exacerbations. The following
    endpoint will be evaluated:
    ? Rate of COPD exacerbations per patient per year (all categories except
    moderate or severe, which is done in the primary endpoint, mild, treated
    with antibiotics only) . The following endpoints will be evaluated:
    ? Proportion of patients experiencing a COPD exacerbation (all
    categories except mild, treated with antibiotics only)
    ? Time to first COPD exacerbation (all categories except mild, treated
    with antibiotics only)
    ? Number of COPD exacerbation days (all categories)
    ? Duration of COPD exacerbations (all categories)
    ? Time to second COPD exacerbation of moderate or severe COPD
    exacerbations
    ? Time to third COPD exacerbation of moderate or severe COPD
    exacerbations
    ? Number needed to treat (NNT) to avoid one moderate or severe COPD
    exacerbation
    ? Frequency of COPD exacerbations (all categories)
    Lung function endpoints (post-bronchodilator)
    Change from randomisation (V2) over 52 weeks of treatment for:
    ? FVC [L]
    ? Forced expiratory flow at 25% to 75% of vital capacity (FEF25-75%
    [L/s])
    ? Forced expiratory volume in the first 6 seconds (FEV6 [L])
    ? FEV1/FVC [%]
    Diary endpoints
    ? Use of rescue medication (change from randomisation [W0 = last week
    prior to randomisation] over 52 weeks of treatment)
    ? COPD symptom scores: score sum, cough, sputum (change from
    randomisation [W0] over 52 weeks of treatment)
    ? Proportion of symptoms free days
    ? Proportion of rescue medication free days
    Quality of life
    ? COPD Assessment Test (CAT; change from randomisation [V2] over 52
    weeks of treatment)
    Mortality
    ? Time to mortality due to any reason
    ? Time to mortality due to a COPD exacerbation
    Time to trial withdrawal
    ? Time to trial withdrawal during the treatment period
    ? Time to trial withdrawal due to a COPD exacerbation during the
    treatment period
    ? Time to trial withdrawal due to an AE during the treatment period
    Criterio secundario de valoración clave: - Cambio desde la aleatorización (V2) durante 52 semanas de tratamiento del FEV1 [L]
    después del broncodilatador
    Otros criterios secundarios de valoración:
    Las categorías de EPOC analizadas son: leve5; moderada; grave; moderada o grave; leve, moderada o grave; exacerbaciones de la EPOC tratadas con glucocorticoides sistémicos y/o antibióticos; exacerbaciones de la EPOC tratadas con antibióticos sólo; exacerbaciones moderadas o graves y/o tratadas con antibióticos y exacerbaciones de la EPOC registradas en el CRD6. Se evaluarán los siguientes criterios de valoración:
    ? Tasa de exacerbaciones de la EPOC por paciente y año (todas las categorías excepto las exacerbaciones moderadas o graves, que se realiza en el criterio principal de valoración, las exacerbaciones leves y las tratadas con antibióticos sólo)
    ? Proporción de pacientes que experimentan una exacerbación de la EPOC (todos los grupos excepto leve, tratada con antibióticos sólo)
    ? Tiempo hasta la primera exacerbación de la EPOC (todos los grupos excepto leve, tratada con antibióticos sólo)
    ? Número de días de exacerbación de la EPOC (todos los grupos)
    ? Duración de las exacerbaciones de la EPOC (todos los grupos)
    ? Tiempo hasta la segunda exacerbación de la EPOC de exacerbaciones moderadas o graves de la EPOC
    ? Tiempo hasta la tercera exacerbación de la EPOC de exacerbaciones moderadas o graves de la EPOC
    ? Número de sujetos que es necesario tratar (NNT) para prevenir una exacerbación moderada o grave de la EPOC
    ? Frecuencia de las exacerbaciones de la EPOC (todos los grupos)

    Criterios de valoración de la función pulmonar (después del broncodilatador)
    Cambio desde la aleatorización (V2) durante 52 semanas de tratamiento para:
    ? FVC [l]
    ? Flujo espiratorio forzado del 25% al 75% de la capacidad vital (FEF25-75% [l/s])
    ? Volumen espiratorio forzado en los primeros 6 segundos (FEV6 [l])
    ? FEV1/FVC [%]

    Criterios de valoración del diario
    ? Uso de medicación de rescate (cambio con respecto a la aleatorización [S0 = semana
    previa a la aleatorización] durante 52 semanas de tratamiento)
    ? Puntuaciones de los síntomas de EPOC: suma de puntuación, tos, esputo (cambio
    desde la aleatorización [S0] durante 52 semanas de tratamiento)
    ? Proporción de días sin síntomas
    ? Proporción de días sin medicación de rescate
    Calidad de vida
    ? Prueba de evaluación de la EPOC (CAT; cambio desde la aleatorización (V2) durante
    52 semanas de tratamiento)
    Mortalidad
    ? Tiempo hasta la muerte por cualquier motivo
    ? Tiempo hasta la muerte por una exacerbación de la EPOC
    Tiempo hasta la retirada del ensayo
    ? Tiempo hasta la retirada del ensayo durante el período de tratamiento
    ? Tiempo hasta la retirada del ensayo por una exacerbación de la EPOC durante el
    período de tratamiento
    ? Tiempo hasta la retirada del ensayo por un AA durante el período de tratamiento
    E.5.2.1Timepoint(s) of evaluation of this end point
    The 1-year treatment period is considered appropriate to investigate the effects of the drug substance on the secondary endpoints on exacerbations, Lung Function, Symptoms and Quality of Life, taking into account the seasonal variation of COPD exacerbations during the year.
    El periodo de tratamiento de un año se considera adecuado para investigar los efectos del fármaco en las variables secundarias sobre las exacerbaciones, la función pulmonar, los síntomas y la calidad de vida, teniendo en cuenta la variación estacional de las exacerbaciones de la EPOC durante el año.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) Yes
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned9
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA95
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Brazil
    Canada
    Israel
    Korea, Democratic People's Republic of
    Russian Federation
    South Africa
    Turkey
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    For all randomised patients who completed the trial treatment period as scheduled, one follow-up visit with further protocol-specified assessments is implemented 12 weeks after end of the treatment period. All parties involved in the trial will remain blinded between the end of the treatment period and the follow-up visit (VFU). The end-of-trial is defined as database hard-lock, which will be subsequently to the follow-up visit of the last patient
    Para todos los pacientes aleatorizados que completen el periodo de tratamiento como está previsto, se implementará una visita de seguimiento (VS), con más evaluaciones especificadas de protocolo, 12
    semanas después del final del periodo de tratamiento. Se mantendrá el enmascaramiento para todas las partes implicadas en el ensayo entre el final del periodo de tratamiento y la VS. El final del estudio se
    define como el cierre de la base de datos, que será después de la VS del último paciente.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months8
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months8
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1Number of subjects for this age range: 0
    F.1.1.1In Utero No
    F.1.1.1.1Number of subjects for this age range: 0
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.2.1Number of subjects for this age range: 0
    F.1.1.3Newborns (0-27 days) No
    F.1.1.3.1Number of subjects for this age range: 0
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.4.1Number of subjects for this age range: 0
    F.1.1.5Children (2-11years) No
    F.1.1.5.1Number of subjects for this age range: 0
    F.1.1.6Adolescents (12-17 years) No
    F.1.1.6.1Number of subjects for this age range: 0
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 0
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 0
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state53
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 1475
    F.4.2.2In the whole clinical trial 3002
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    there are no plans for further treatment by the sponsor
    El promotor no prevé más tratamiento.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2011-05-30
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2011-05-04
    P. End of Trial
    P.End of Trial StatusCompleted
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2019 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA